Ifinatamab deruxtecan
| Clinical data | |
|---|---|
| Other names | DS-7300 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
| KEGG | |
Ifinatamab deruxtecan (DS-7300) is an experimental anti-cancer treatment developed by Merck and Daiichi Sankyo. It is an antibody–drug conjugate that "consists of an anti-B7-H3 antibody linked with a DNA topoisomerase I inhibiting anti-tumor agent".